BUSINESS
Business Overview
By safely returning medical information to patients, we transfer data sovereignty back to the patients themselves. This makes real-time consent (dynamic consent) possible at the moment of AI use, resolving the "third-party provision risk" that medical institutions face under Japan's Personal Information Protection Act — and providing the only domestic infrastructure that enables safe and sustainable development and operation of medical AI.
When data is used for secondary purposes, our "revenue-sharing" model distributes the proceeds between medical institutions and patients.
-
Only in Japan
Medical AI Infrastructure
The only consent-management foundation that frees medical institutions from third-party-provision risk.
-
Real-time
Dynamic Consent
Per-use approval from the patient's smartphone — compatible with AI updates.
-
Fair circulation
Revenue-Sharing Model
A mechanism that returns secondary-use revenue to medical institutions and patients.
Healthcare DX Solutions
We deliver "Health Interview," an operational support system that brings together patient information return, consent acquisition, and generative-AI use, alongside "Medireco," our medical-information management app for patients — enabling efficiency in hospital operations, regional medical collaboration, and monetization of medical data.
Learn more →
Next-Generation Medical Registry Infrastructure
A next-generation medical information exchange platform that lets research institutions, pharmaceutical companies, and SaMD developers contract directly with patients through smart contracts. With patient consent, non-anonymized medical information can be searched, purchased, and used safely and rapidly — drastically reducing the time and effort traditionally spent on ethics reviews, procedures, and data collection.
Learn more →The Social Challenge
Putting generative AI to work in clinical settings usually requires connecting electronic medical record data to an external AI provider — which risks qualifying as "third-party provision" under Japan's Personal Information Protection Act. Because medical information is a "special-care required" category that does not allow opt-out, and because conventional blanket consent cannot specify purpose nor accommodate AI updates, medical institutions end up bearing the legal and ethical risk of "third-party provision without patient consent."
This "consent barrier" is structurally stalling medical-AI innovation in Japan.
Before
Blanket-Consent Model
- Difficult to specify purpose of use
- Does not accommodate AI updates
- Third-party-provision risk falls on the institution
- Medical-AI innovation stalls
AIBTRUST
Dynamic Consent
- Purpose-specific consent per AI use
- Individual approval on every update
- Data sovereignty rests with the patient
- Institutions are freed from legal risk
AIBTRUST's Approach
AIBTRUST solves this problem at its root through two novel approaches: "information return" to the patient and "dynamic consent."
- 01
Information Return
Diagnostic data is returned to the patient through blockchain technology, transferring data sovereignty back to the individual.
- 02
Real-Time Consent
At the moment of AI use, a notification is sent to the patient's smartphone to obtain dynamic approval.
- 03
Safe AI Use
Institutions are freed from third-party-provision risk and can confidently apply generative AI to hospital operations.
We deliver the only infrastructure in Japan that lets medical institutions use AI safely, without bearing legal risk.
Glossary
Dynamic Consent
A method of obtaining consent from patients online, on each occasion. By specifying the purpose of AI use, it manages data-use authorization based on the patient's real-time intent — the next-generation alternative to blanket consent.
Registry
A database that collects and continuously tracks clinical information and test results for a specific disease or treatment, serving as a foundation for research.
Smart Contract
A mechanism on the blockchain that automatically executes a contract or transaction when pre-programmed conditions are met.